Cipla in talks with Eli Lilly for diabetes drug, say sources; shares in green

Cipla share price news, Cipla-Eli Lilly News: Cipla is in talks with US-based Eli Lilly to manufacturer Semaglutide and Ozempic — anti-diabetic medications — in India, sources told Zee Business. The Cipla stock held on firmly to the green after the news. 

Initially, Eli Lilly will share technology with Cipla, which will later produce these drugs on its own, added the sources. 

There is strong demand for Ozempic in the country.

At the time of publishing this report, queries emailed to Cipla remained unanswered.

Cipla share price news

The Cipla stock ended higher by Rs 9, or 0.6 per cent, for the day at Rs 1,601.3 apiece on BSE, having gained as much as 1.0 per cent to Rs 1,607.6 apiece during the session. 

The pharma stock traded with moderate volumes with about 20,000 shares changing hands for the day on BSE, lower than a daily average of 44,000 recorded in the past two weeks, according to provisional exchange data. 

Cipla shares vs Nifty 50 vs Nifty Pharma 

At the current level, Cipla shares have risen 4.8 per cent so far in 2025, in line with a 5.2 per cent gain in the Nifty50 though outperforming a 4.7 per cent in the Nifty Pharma.

Cipla Q1 FY26 Results 

Last month, the Mumbai-based pharmaceutical firm staged a strong financial performance for the first quarter of the current financial year.

Its consolidated net profit grew 10.2 per cent to Rs 1,298 crore, beating analysts’ expectations.

ALSO READ: Cipla Q1 FY26 Results | With Rs 1,298 crore Q1 profit, Mumbai-based pharma company beats Street estimates

How analysts view Cipla shares

Most analysts view Cipla shares positively.  

Brokerage Axis Direct has a ‘buy’ call assigned to the Cipla stock with a target price of Rs 1,700. 

At Friday’s closing price, the target suggests an upside of 6.8 per cent in the largecap pharma stock.